Covered recipient · General Payments record
MIKE CUSNIR
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$20,154.30
380 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,310.00 | 4 |
| Food and Beverage | $7,925.70 | 371 |
| Consulting Fee | $2,720.00 | 3 |
| Education | $198.60 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MIKE CUSNIR
NPI 1962490631 · CMS profile ID 88663
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
MIAMI BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MIKE CUSNIR, NPI 1962490631, CMS profile ID 88663. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MIKE CUSNIR, NPI 1962490631, CMS profile ID 88663. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MIKE CUSNIR, NPI 1962490631, CMS profile ID 88663, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 8; records 351–380 of 380 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1962490631?year=2024&recipient=provider&page=8#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
380 matching records · $20,154.30 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 351–380 of 380.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.84 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141560850 | CMS |
| Janssen Biotech, Inc. | $23.29 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078454585 | CMS |
| GENZYME CORPORATION | $28.19 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139689884 | CMS |
| Janssen Biotech, Inc. | $5.91 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078454730 | CMS |
| ARRAY BIOPHARMA INC | $630.00 | 01/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131311091 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.67 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104517608 | CMS |
| Celgene Corporation | $17.30 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101184599 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.83 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105881862 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $107.95 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086122316 | CMS |
| BeiGene USA, Inc. | $13.77 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120858203 | CMS |
| Janssen Biotech, Inc. | $6.62 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078454118 | CMS |
| PFIZER INC. | $20.64 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131106917 | CMS |
| BeiGene USA, Inc. | $15.64 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120858205 | CMS |
| Adaptive Biotechnologies Corporation | $20.72 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150261096 | CMS |
| Ipsen Biopharmaceuticals, Inc | $820.00 | 01/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091951501 | CMS |
| Janssen Biotech, Inc. | $18.52 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078454611 | CMS |
| Mirati Therapeutics, Inc. | $22.58 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117176735 | CMS |
| AstraZeneca Pharmaceuticals LP | $31.41 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105795094 | CMS |
| Incyte Corporation | $29.54 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141207173 | CMS |
| Celgene Corporation | $30.57 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101184603 | CMS |
| EMD Serono, Inc. | $20.00 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120224553 | CMS |
| PFIZER INC. | $14.52 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131158218 | CMS |
| TAIHO ONCOLOGY, INC. | $19.93 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137940902 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.49 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144955793 | CMS |
| PFIZER INC. | $16.75 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131302181 | CMS |
| Eisai Inc. | $26.25 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110766851 | CMS |
| Janssen Biotech, Inc. | $18.25 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078454389 | CMS |
| PFIZER INC. | $13.86 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131296081 | CMS |
| Merck Sharp & Dohme LLC | $17.77 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141823421 | CMS |
| Novartis Pharmaceuticals Corporation | $15.47 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086722397 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $554,620.22 | 87 |
| PY2024 | Principal investigator | $514,545.35 | 83 |
| PY2023 | Principal investigator | $254,771.60 | 107 |
| PY2022 | Principal investigator | $174,461.99 | 49 |
| PY2021 | Principal investigator | $95,929.81 | 71 |
| PY2020 | Principal investigator | $86,337.27 | 73 |
| PY2019 | Principal investigator | $126,177.02 | 70 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
87 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $3,975.00 | 12/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | C-906289-002 | No dispute reported | 06/30/2026 | 1249029789 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 12/12/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477645 |
| Principal investigator 1 | Incyte Corporation | $313.00 | 12/12/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477648 |
| Principal investigator 1 | Incyte Corporation | $313.00 | 12/12/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477653 |
| Principal investigator 1 | PFIZER INC. | $5,032.00 | 11/25/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $860.00 | 11/10/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175390845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $610.00 | 10/20/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175390857 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,276.98 | 10/15/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211415411 |
| Principal investigator 1 | PFIZER INC. | $315.00 | 10/14/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709179 |
| Principal investigator 1 | PFIZER INC. | $3,100.00 | 10/14/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709181 |
| Principal investigator 1 | Genmab U.S., Inc. | $380.00 | 10/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925990 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,378.75 | 10/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925996 |
| Principal investigator 1 | Incyte Corporation | $80.82 | 10/06/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477641 |
| Principal investigator 1 | Incyte Corporation | $53.88 | 10/06/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477657 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 09/22/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718483 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 09/22/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718600 |
| Principal investigator 1 | Exelixis Inc. | $567.00 | 09/19/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222377274 |
| Principal investigator 1 | PFIZER INC. | $8,865.00 | 09/19/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A PHASE 2 RANDOMIZED OPENLABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600EMUTANT MSI HDMMR METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228710844 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 09/19/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717337 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 09/19/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228717339 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $40,393.84 | 09/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | NCT02360579 | No dispute reported | 06/30/2026 | 1252498107 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $625.00 | 09/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | NCT02360579 | No dispute reported | 06/30/2026 | 1252498109 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $9,695.00 | 09/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | NCT02360579 | No dispute reported | 06/30/2026 | 1252498111 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $500.00 | 09/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | NCT02360579 | No dispute reported | 06/30/2026 | 1252498113 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $250.00 | 09/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | NCT02360579 | No dispute reported | 06/30/2026 | 1252498115 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,105.00 | 09/12/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175390841 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 09/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477621 |
| Principal investigator 1 | Incyte Corporation | $21.40 | 09/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477624 |
| Principal investigator 1 | Incyte Corporation | $53.88 | 09/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477629 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 09/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477632 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 09/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT 302) | No dispute reported | 06/30/2026 | 1240477637 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,560.42 | 08/31/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 1,2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers | No dispute reported | 06/30/2026 | 1232932890 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,160.00 | 08/26/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925986 |
| Principal investigator 1 | PFIZER INC. | $17,961.00 | 08/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709006 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,989.38 | 08/06/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211416848 |
| Principal investigator 1 | PFIZER INC. | $4,562.50 | 08/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A PHASE 2 RANDOMIZED OPENLABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600EMUTANT MSI HDMMR METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228710846 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $850.00 | 08/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | C-906289-002 | No dispute reported | 06/30/2026 | 1249029793 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $625.00 | 07/25/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | C-906289-002 | No dispute reported | 06/30/2026 | 1249030053 |
| Principal investigator 1 | PFIZER INC. | $2,890.00 | 07/21/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709091 |
| Principal investigator 1 | PFIZER INC. | $1,564.00 | 07/21/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709094 |
| Principal investigator 1 | Gilead Sciences, Inc. | $281.25 | 07/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1229211829 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,479.00 | 07/18/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211419659 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $1,331.00 | 07/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530001 |
| Principal investigator 1 | PFIZER INC. | $4,280.00 | 06/30/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709454 |
| Principal investigator 1 | PFIZER INC. | $1,564.00 | 06/30/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228710684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,780.00 | 06/27/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175390835 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,640.00 | 06/27/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175391020 |
| Principal investigator 1 | Novocure Inc. | $1,875.00 | 06/26/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856335 |
| Principal investigator 1 | PFIZER INC. | $20,711.26 | 06/25/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228711012 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $452.50 | 06/24/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211419665 |
| Principal investigator 1 | PFIZER INC. | $625.00 | 06/23/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709274 |
| Principal investigator 1 | PFIZER INC. | $2,267.00 | 06/23/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709276 |
| Principal investigator 1 | PFIZER INC. | $495.00 | 06/23/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228710360 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,479.00 | 06/13/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211417513 |
| Principal investigator 1 | PFIZER INC. | $26,328.00 | 06/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709278 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,817.08 | 06/05/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211416122 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $15,639.14 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | C-906289-002 | No dispute reported | 06/30/2026 | 1249029941 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,340.00 | 05/29/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175390983 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,601.00 | 05/29/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175390996 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,490.00 | 05/29/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175391080 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,250.00 | 05/28/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211419661 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $1,331.00 | 05/19/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236529997 |
| Principal investigator 1 | Exelixis Inc. | $1,637.10 | 05/16/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222377272 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $452.50 | 05/15/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211418943 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,250.00 | 05/08/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925982 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $14,633.46 | 05/08/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211419663 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/15/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228834858 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/14/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228822912 |
| Principal investigator 1 | PFIZER INC. | $1,050.00 | 04/07/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228710682 |
| Principal investigator 1 | PFIZER INC. | $2,820.00 | 03/31/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709096 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 03/27/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228834845 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 03/27/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228834853 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 03/26/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228822831 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 03/26/2025 | Non-covered Recipient Entity Mount Sinai Comprehensive Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228822917 |
| Principal investigator 1 | Exelixis Inc. | $6,807.60 | 03/21/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222377270 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $900.00 | 03/20/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | NCT02360579 | No dispute reported | 06/30/2026 | 1252496833 |
| Principal investigator 1 | PFIZER INC. | $437.50 | 03/13/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228709177 |
| Principal investigator 1 | PFIZER INC. | $13,075.20 | 03/13/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228711014 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,479.00 | 03/13/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211417511 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $17,022.54 | 03/06/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. | No dispute reported | 06/30/2026 | 1211416120 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,100.00 | 02/20/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925978 |
| Principal investigator 1 | Exelixis Inc. | $3,373.20 | 01/24/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222377268 |
| Principal investigator 1 | Genmab U.S., Inc. | $580.00 | 01/23/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925964 |
| Principal investigator 1 | Genmab U.S., Inc. | $625.00 | 01/16/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925971 |
| Principal investigator 1 | Novocure Inc. | $900.00 | 01/16/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856583 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,050.00 | 01/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925967 |
| Principal investigator 1 | Genmab U.S., Inc. | $531.60 | 01/09/2025 | Covered Recipient Teaching Hospital Mount Sinai Medical Center Of Florid | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235925974 |